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Background: Rheumatoid Arthritis (RA) is an autoimmune disease with autoantibodies 
leading to a localized inflammation reaction in the joints. An important type of antibody 
involved in RA include antibodies against citrullinated peptides/proteins. Citrullination is 
a normal cellular process, however, RA is marked by a state of pathologic 
hypercitrullination. Specific risk factors, such as genetic predisposition, gender, and 
smoking, have been identified as contributing to the development of RA, but the 
mechanism behind how autoantibodies lead to RA pathology, what leads to pathological 
hypercitrullination and the generation of anti-citrullinated protein antibodies (ACPA) is 
insufficiently understood. It has been established that RA patients have antibodies to 
human endogenous retroviruses (HERVs), and more specifically, to the HERV-K family 
of such viruses. HERV-Ks are ancient retroviruses that have been integrated into the 
human genome and rendered inactive due to the accumulation of mutations. However, the 
presence of HERV-K antibodies suggests that there may be the capability to restore viral 
transcription in certain cases. If HERV-K was to be expressed, it would elicit the same 
immune reaction that exogenous viruses do, however, since it is a part of the human 




Objective: This thesis aims to explore the RA immune response to HERV-K, with a 
focus on neutrophils. Further, the relationship between HERV-K immunity and 
pathological hypercitrullination will also be explored. 
Methods: Our studies utilized protein/antibody detection techniques to quantitate 
specific proteins/antibodies in sera and leukocytes isolated from RA patients. These 
techniques included enzyme-linked immunosorbent assay (ELISA), flow cytometry, and 
western blot analysis. Antibodies against HERV-K envelope (Env), an important viral 
protein, and citrullinated-Env (citEnv) were affinity-purified from patient sera to be used 
in these experiments. 
Results: Our experiments first replicated a result that has been previously established in 
the literature: RA patients produce antibodies against HERV-K. More specifically, we 
found that RA patient’s Env antibodies almost exclusively recognize the surface portion 
of the protein. Our data also presents the finding that patient antibodies are more reactive 
to citEnv than they are to unmodified Env, and that citEnv is expressed on patient 
neutrophils. Lastly, we found that some patient neutrophils are associated with the 
membrane attack complex of complement. 
Conclusion: The fact that RA patient’s neutrophils express citEnv suggests a link 
between HERV-K and the pathological hypercitrullination that’s a hallmark of RA. 
Additionally, the association of the membrane attack complex (MAC) with patient 
neutrophils suggests a potential mechanism of how this may occur: neutrophils express 
Env (following the re-initiation of HERV-K transcription), which then undergo 




to complement activation and eventually MAC-induced neutrophil lysis. In doing so, 
neutrophils, which are enriched in citrullinating enzymes, can spill such enzymes into the 
extracellular space, leading to further citrullination and ACPA development. Further 
studies need to be done to confirm these data, as well as to fill gaps in knowledge 
regarding the novel hypothesis that HERV-K expression in RA patients may play a role 
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Arthritis is the leading cause of disability in the United States. Fifty-four million 
adults have been diagnosed with arthritis, with recent studies projecting that when 
accounting for undiagnosed cases, over 90 million Americans actually suffer from 
arthritis (1). As an umbrella term, arthritis refers to joint pain/disease and encompasses at 
least one hundred different diseases and related conditions. Of these different “arthritis” 
diseases, RA is one of the most prevalent, affecting 1.5 million Americans, with 41 out 
of 100,000 people developing the disease annually (2). Patients with RA have a 54% 
higher mortality risk compared to the general population, and RA accounts for 22% of 
deaths associated with arthritis (3,4). RA patients often also face significant disability: 
20-70% of individuals who were working when diagnosed with RA were disabled in 7-10 
years, and 25-50% of all patients with RA become unable to work within 10-20 years 
post-diagnosis (1). RA patients are about 1.5 times more likely to need help with personal 
care and 1.3 times more likely to have health-related activity limitation in comparison to 
people without RA (5). RA can impart substantial financial burden, as well. In 2009, 
43.6% of RA patients had trouble paying medical and drug bills. The total annual societal 
cost of RA was $39.2 billion in 2005 (1). 
Clinical Manifestations 
 
RA is characterized by dysregulated inflammatory processes in joint synovia, 
leading to progressive and irreversible damage resulting in the loss of joint space, 
function, and deformity. Extracellular matrix degradation also occurs, resulting in the loss 




damaged and the resulting pain in these joints is a hallmark of RA. However, most joints 
in the body are susceptible to damage. Outside of the joints, systemic inflammation 
associated with RA has been connected to a variety of other symptoms including 
subcutaneous nodules, eye inflammation, lowering of the white blood count, and lung 
disease (6,7). Systemic symptoms such as malaise, low-grade fever, depression, and 
fatigue, often precede other symptoms and can serve as indicators of underlying disease. 
Symptoms can come and go from one day to the next, or even within one day (7). 
While there is not one uniform clinical presentation of RA, 75% of patients 
experience a gradual onset of pain with swelling in the small joints (7). RA is 
characteristically symmetric; thus, patients experience symptoms on both sides of the 
body at the same time. Symptoms include swelling, tenderness, stiffness, and motion 
impairment of involved joints. Commonly affected joints include: the 
proximal interphalangeal (PIP) and metacarpophalangeal (MCP) joints of the hands, 
wrists, elbows, knees, ankles, and the small joints of the feet including the 
metatarsophalangeal (MTP) joints (Figure 1) (6,7,9). Over time, some RA patients may 







Figure 1: Joints Commonly Affected by Rheumatoid Arthritis (9) 
In 2010, the American College of Rheumatology (ACR) and the European League 
Against Rheumatism (EULAR) formed a joint committee to develop a system to classify 
RA and streamline the diagnosis process. These classification criteria can be applied to 
any patient who has active joint inflammation that can’t be explained by another 
diagnosis. Numerical scores are given in the following categories: joint involvement, 
serology, acute phase reactants, and duration of symptoms. If the sum of a patient’s 
scores meets a certain threshold, that person is given a RA diagnosis (8). 
HERV-K 
 
Human endogenous retroviruses (HERVs) have recently been implicated in the 
development of RA (10-14). Retroviral genomes are composed of RNA, which is 
converted to dsDNA via reverse transcription. This DNA is then integrated into the host 
cell genome to form the provirus (10,11). An exogenous virus is one classically thought 




virions. Common human exogenous retroviruses include HIV-1, HIV-2, HTLV-I and 
HTLV-II. Endogenous human retroviruses, on the other hand, are viral elements that 
have been effectively trapped in the human genome. HERVs were first integrated into the 
human genome 30–40 million years ago. HERV DNA is transmitted like any other gene 
and is found in the DNA of all cells (10,11,12). In fact, HERV DNA makes up about 8% 
of the human genome (10,11,12,13). HERVs have a similar gene structure to exogenous 
retroviruses, being composed of gag, pol, and env regions flanked by two long terminal 
repeats (LTRs) at each end (Figure 2). Gag is a polyprotein and is an acronym for group- 
specific antigens, Pol includes enzymes for viral replication (reverse transcriptase), 
integration (integrase), and protein cleavage (protease), and Env is the envelope protein 
that recognizes and binds to specific cellular surface molecules which act as viral 
receptors. Env also directs the fusion of the retrovirus membrane with the cellular 
membrane, initiating infection. Due to its plasma membrane location, portions of Env 
may also be immunogenic. Each provirus includes an LTR at its 5’ and 3’ ends. LTRs 
contain promoter and enhancer regions, regulating retroviral transcription, and in turn, 







Figure 2: HERV-K Structure and Integration into the Host Genome 
 
Over time, HERVs have accumulated numerous mutations. Most HERVs are 
defective due to these mutations, however, exceptions able to produce viral particles have 
been discovered. HERV-K (HML-2), is the youngest HERV family, being integrated the 
most recently. It is one of the most transcriptionally active endogenous viral families, for 
these viruses can retain intact open reading frames that encode viral proteins 
(11,12,13,14). In fact, HML-2 transcripts and proteins have been detected in both healthy 
tissues and in malignancies (11,12,14). The contributions of HERV-K to disease 
pathology are currently being studied in a variety of fields including oncology, 
neurology, and rheumatology (14). HERVs have recently been implicated in development 
of RA, based on elevated antibody titers observed in patients with RA (11,12). This 




antibody response toward HERV-K proteins in patients with RA, which indicates a 
protein exposure (12). 
Autoimmunity 
 
The majority of RA patients are classified as ‘seropositive,’ with certain 
autoantibodies found in their blood. The presence of these antibodies will often precede 
symptom development (15,16). Of the autoantibodies that are found in RA patients, 
rheumatoid factor (RF), which are antibodies directed against the Fc portion of 
immunoglobulins, and ACPAs against citrullinated proteins/peptides are the most 
common (15,16,17). 
RFs are produced by B cells within secondary lymphoid organs. They constitute a 
normal component of the physiological response to antigenic stimuli (16,17,18). RFs 
directly bind to the Fc portion of various immunoglobulin isotypes (IgG, IgA and IgM), 
but IgM-RF is detected in 60–80% of RA patients and is used for diagnostic testing 
(16,17). Pathologic RFs arise through rearrangements and somatic hypermutations of the 
germline genes (18). They then go through affinity maturation, the process by which B 
cells produce antibodies with increased affinity for a specific antigen. Physiologically 
normal RFs don’t undergo affinity maturation and remain polyreactive and of low affinity 
(17). RFs have a low specificity, as they are present in other rheumatic diseases, as well 
as healthy individuals (16,17). 
RFs normally exert their effect in a number of ways. They bind to and increase 
the stability of IgG bound to antigens, increasing the size and stability of immune 




cells take up such complexes, to effectively function as an antigen presenting cell, along 
with facilitating complement fixation and leukocyte infiltration (16,17,18). As stated 
above, RFs become pathogenic after affinity maturation. In RA, such antibodies are 
found in the synovium of joints where they can promote inflammation and antigen 
trapping by performing their normal functions of forming immune complexes, increasing 
the efficiency of antigen presenting cells (APCs), and activating complement, just with 
higher affinity and in increased numbers, which is noted by higher RF titers in RA, 
compared to healthy individuals (16,17). 
ACPAs are found in 70–90% of RA patients and are rarely found in other diseases 
or in healthy individuals (17). ACPAs can also be referred to as antiperinuclear factor 
(APF), antikeratin (AKA), or antifilaggrin (AFA), depending on the antigens used for 
their detection (16,17,19). While the proteins recognized by these antibodies differ, they 
all recognize citrullinated residues and will not recognize these proteins in the absence of 
citrulline (17). Citrullinated autoantigens are the most studied, however, there is also 
evidence of autoimmunity to peptides that have had other kinds of post-translational 
modifications, including carbamylated (ACarPAs) and acetylated proteins/peptides 
(AAPAs) (15). Note that as previously stated, not all RA patients have autoantibodies; 
seronegative RA patients represent 10-40% of RA patients, and there is current debate on 
whether seronegative RA should be considered “true” RA (15). 
If HERV-K expression is turned on in cases of RA, virions would elicit the same 
immune response that exogenous viruses do; antibodies would be generated against 




downstream immune responses (35,11). If these proteins were citrullinated, then the 
appropriate ACPA would be produced. However, since this virus is integrated into the 
host genome, it cannot be completely removed and any cell that subsequently expresses 
viral antigens would be recognized as a re-infected cell, becoming a target of the immune 
system. Such a process could be an early event in the production of autoantibodies, 
breaking the tolerance to autoantigens (11). 
Citrulline is a non-essential amino acid, meaning that it doesn’t necessarily need 
to be obtained from food, as it can be produced in the body, as the result of a post- 
translational modification of proteins/peptides (20). Citrullination is a part of normal 
physiology and is required for skin formation, among other physiologic functions (21). 
Citrullination involves the deimination (removal of an imine) of an arginine residue in a 
protein/peptide (Figure 3). Since arginine is positively charged and citrulline carries no 
charge, this conversion results in the loss of one positive charge. This reduction in net 
charge increases hydrophobicity and protein denaturing, and changes intra- and inter- 
molecular interactions, all leading to a change protein function (20,22). A class of 
enzymes, the peptidylarginine deiminases (PADs), are responsible for causing 
citrullination to occur (20-24). Humans have five PADs: PAD1, PAD2, PAD3, PAD4 
and PAD6 (20,21). Neutrophils, in particular, are enriched for PAD2 and PAD4. PAD 
activation is controlled by calcium concentration (20,21,23,24). Dysregulated PAD 
activity, most notably PAD2 and PAD4, is associated with multiple inflammatory 







Figure 3: The Citrullination Reaction (22) 
 
Hypercitrullination, the citrullination of an abnormally high number of proteins, 
can occur within synovial fluid (SF) cells of RA patients (20-24). The RA citrullinome (a 
collective view of citrullinated proteins) is comprised of both intracellular and 
extracellular proteins (20). PAD activation is regulated by calcium concentration, with an 
optimal concentration of 1-5 mM needed for activation. Average calcium concentration is 
150 nM intracellularly, and 1-2 mM extracellularly (23). Intracellularly, the necessary 
calcium influx needed to activate, and hyper-activate PADs, must be accomplished by 
disruption of the cell membrane, which would allow enough calcium to flow down its 
concentration gradient into the cell. This assault on the membrane can come by way of 
the activation of the membrane attack complex (MAC) of the complement system, the 
pore-forming protein perforin, bacterial toxins, and calcium ionophores (20,23,24). While 
the extracellular space may have sufficient concentration of calcium to hyperactivate 
PADs, these proteins are contained to the intracellular space. However, as stated above, 




from the intracellular space to the extracellular space during neutrophil cell death/lysis or 
NETosis, or, from damaged/dying cells (20,24). 
Neutrophils are a particular cell of interest when it comes to the study of RA. First 
off, neutrophils are the first cells recruited to the site of inflammation/infection and play a 
big role in inflammatory processes. Once neutrophils leave the circulation by way of 
diapedesis, they can begin to express key surface receptors and cyto-/chemokines, further 
activating and recruiting other immune cells (25-27). They also phagocytose pathogens. 
The resulting phagosome merges with a lysosome containing preformed antimicrobial 
agents chemicals, such as reactive oxygen species (ROS) and myeloperoxidase, leading 
to the death and degradation of the pathogen (25,26,27). Thus, as a major player in the 
inflammatory process, neutrophils mediate and promote the increased inflammatory 
environment that is a hallmark of RA. Neutrophils can also trap pathogens in a process 
coined NETosis. During this process, the neutrophils release their chromatin and granule 
enzymes in a mesh-like structure that can both trap and kill pathogens. While this process 
is successful in killing pathogens, these neutrophil extracellular traps (NETs) can also 
serve as a source of autoantigens (25,26,27). Additionally, as previously stated, this 
process could potentially release PADs into the extracellular space, and lead to the 
citrullinated extracellular proteins that are seen in the RA citrullinome (20,24). In fact, 
several neutrophil-associated proteins are included in the RA citrullinome. Lastly, 
neutrophils isolated from patients with RA are simply different than neutrophils isolated 




activity, increased production of ROS, increased migratory capacity and cell survival, and 
an exacerbated release of NETs (25,26,27). 
Figure 4: Mechanisms of Normal and Dysregulated Citrullination (20) 
 
If an RA patient’s neutrophils were to express Env, these proteins could either be 
recognized by antibodies against Env, or undergo citrullination and get recognized by 
ACPAs, stimulating an immune response in both cases. These cells would then be killed 
as a result of complement fixation and/or by cytotoxic T-Cells (11). These processes 
would compromise the cell membrane and in doing so, lead to a rush of calcium into the 
neutrophils causing PAD activation and hypercitrullination. PADs could also leak out of 
the cell into the calcium-rich extracellular space, where they can become activated and 
citrullinate extracellular targets (11,20,24). 
Since citrullinated proteins are present in healthy individuals and are required for 
normal processes, production of ACPAs represents a break in tolerance, or in the ability 




Uncontrolled PAD activity may lead to nonselective citrullination, creating neo- 
citrullinated proteins that the immune system has not built a tolerance for. If this was to 
occur, these proteins could trigger an autoimmune response (21). Multiple risk factors for 
RA have been implicated in the development of the immune response against 
citrullinated proteins and ACPA formation. 
Risk Factors 
 
The heritability, or the contribution of genetic variation to the variation in disease 
status, of RA is about 60% (28,29,30). This heritability is not yet completely understood, 
but it has been shown that there is an increased disease prevalence in females and a 
strong risk association with specific human leukocyte antigen (HLA) alleles. Over two- 
thirds of RA patients are female (2). Not only are females diagnosed with RA more than 
males, but they are also less likely to go into remission than their male counterparts (32). 
A significant difference between women and men in disease activity at the onset of 
disease has not been shown, however it has been shown that disease course is worse in 
women (31,32). Why women are more likely to get RA and face less remission and a 
worse disease course when they do, is not completely understood. A number of factors 
have been proposed and are being actively studied. X-linked genetic factors, hormonal 
factors, and exposures that may be different for men and women could all influence the 
prevalence of RA and its severity (31). One common hypothesis explains the RA gender 
gap with the fact that estrogens exert pro-inflammatory effects while androgens exert 
anti-inflammatory effects. It has been found that the conversion of androgens to estrogens 




has also been proposed that subjective factors, such as a differing treatment and pain 
thresholds of men and women can lead a gap in the measurement of the disease, rather 
than a difference in disease activity itself (31). HERV-K may also play a role in 
explaining the RA gender bias. The 5’ LTR of HERV-K contains several binding motifs 
for female sex hormones. Estradiol and Progesterone synergistically activate HERV-K 
through nuclear receptors. An isoform of the progesterone receptor binds a progesterone- 
response element in a long terminal repeat (LTR5) of HERV-K (34). These hormones can 
upregulate transcription many-fold, which, if HERV-K contributes to hypercitrullination 
and ACPA formation, would directly promote disease activity. 
Over 100 genetic loci have been identified as being implicated in RA 
susceptibility (29,35). Most of the known genetic heritability of RA is due to variance in 
the major histocompatibility complex (MHC) (28,29). The MHC class II region at 
chromosome 6 confers a distinctive and strong genetic risk when compared with other 
RA risk loci, explaining 30–50% of total genetic risk of RA (30,36). These loci encode 
proteins of the HLA 2 complex, cell surface molecules on antigen presenting cells 
(APCs) (37,38). APCs phagocytose pathogens and migrate to the lymphatic system with 
digested pathogens on these HLA class 2 surface receptors. This receptor serves as an 
accessory protein for antigen binding to the T cell receptor on CD4+ T cells (37). This 
binding activates the T cell to perform a number of functions, including the activation of 
cells of both the innate and adaptive immune system, as well as nonimmune cells (39). 
There are 3 major HLA class II proteins encoded by the MHC: HLA-DP, HLA- 




heterodimeric protein receptors expressed on the surface of APCs. Each class has 
different genes at specific loci to encode the parts of the receptor (32,33,35). HLA-DRB1 
is responsible for the majority of genetic RA risk (25-30,35,36,38,40). The HLA- 
DRB1 alleles that are implicated in RA code for the “shared epitope” (SE): a 5-amino 
acid motif, encompassing amino acids 70-74 in the third hypervariable region (HV3) of 
the DRβ1 molecule. The code is as followed: Q/R-K/R-R-A-A (39,40,41). There are also 
alleles that can code for a protective sequence, D-E-R-A-A, at the same positions (40,43). 
These protein residues are located in the antigen binding site and are thus likely to affect 
antigen presentation. One of the alleles conferring the SE genotype has been shown to 
preferentially bind citrullinated proteins over those with unaltered arginine residues 
(40,42,44). If HLA were to bind to a citrullinated protein, it would then be presented to T 
cells which would then set off the process of ACPA production (39). 
Figure 5: Crystal structure of HLA-DR4 (DRB1*04:01); SE is Shown in Blue (36) 
 
Other genes implicated in RA include PTPN22 and PADI4. The PTPN22 gene 
regulates T and B lymphocyte activity. Two single nucleotide polymorphisms (SNPs) 
in PTPN22 have been linked with autoimmunity: one leads to a gain of function, 




reduced activity (45,46). PADI4 encodes the PAD4 enzyme. PADI4 mRNA is 
significantly overexpressed in RA patients and is detected in pathological synovial tissues 
(47). 
Epidemiological studies have implicated cigarette smoking as an important risk 
factor in RA development (48,49,50). Cigarette smoking increases the risk of RA 
development by 26% in those who smoke 1–10 pack-years and by 94% in those with 
more than 20 pack-years. A pack year is defined as: 
 
Figure 6: Formula of a “Pack year” (48) 
 
Smoking is also associated with the presence of multiple autoantibodies (RF, ACPA, 
ACarPA), with the highest association being with RF. Smoking may also induce 
citrullination of peptide antigens present in the lungs (48,49). It affects both the innate 
and adaptive immunity. In regard to adaptive immunity, smoking is associated with a 
higher ratio of Th1 to Th2 and Th17 T cells (48). In innate immunity, smoking increases 
the levels of several pro-inflammatory cytokines, including TNF, IL-1,IL-6,IL-8,IL-21, 
and IFN (48,49,50). 
Smoking has also been implicated for an interactive effect, especially in relation 
to HLA-DRB1 in seropositive RA cases. Smoking and SE alleles both increase the risk of 
developing seropositive RA, but it has been shown that there is a strong interaction 
between these two risks (48,49,50). The interaction between smoking and other genes 




also been found to have an impact on the activity, severity, and outcome of RA. It has 
been linked to a reduced response to treatment (49,50). Active smoking is associated with 
worse joint inflammation and increased levels of pro-inflammatory cytokines and 
autoantibodies (49). Smoking also appears to contribute to the incidence of extra-articular 
manifestations such as: nodules, diffuse interstitial lung disease, and vasculitis. Whether 
smoking cessation ameliorates any of these effects is a multifactorial issue and is not 
completely understood (50). Smoking has also been shown to increase HERV-K 
transcription, offering an additional potential mechanism as to how smoking promotes 
RA development (11). 
Pathophysiology 
 
It has been well established that autoimmunity can predate RA symptoms by 
years in seropositive disease. Symptoms such as bone loss and arthralgia can often 
predate clinical disease, as well (51,52,53). However, it is not well understood how 
autoimmunity and these pre-clinical symptoms lead to disease. This is an active area of 
research with multiple mechanisms being explored. Proposed mechanisms tend to fall 
under one of two hypotheses: the outside-in disease hypothesis or the inside-out disease 
hypothesis (51). 
The inside-out hypothesis posits that inflammation and structural damage begin in 
the bone and spread to the joint capsule. One mechanism of how this preclinical bone loss 
occurs involves ACPA recognition of and binding to citrullinated vimentin on the surface 
of osteoclast precursors. This binding promotes an osteoclast progenitor cell to 




factor κB ligand (RANKL) and macrophage colony-stimulating factor 1 (M-CSF) induce 
these progenitors to migrate from the bone marrow into the joints causing local osteoclast 
development in the synovial tissue (52). RANKL is a member of the TNF cytokine 
family and is the primary cytokine mediating this process. Differentiation into an 
osteoclast then occurs after the developing progenitor cell comes in contact with the bone 
surface. Osteoclasts express PAD2 and can create additional antigens for ACPAs to bind 
(52). 
IL8 is an autocrine growth factor of osteoclasts and is normally secreted during 
osteoclast differentiation. It has been shown that this still occurs in ACPA-binding 
induced differentiation. Both ACPA immune complexes and IL-8 bind peripheral 
nocioreceptors, initiating IL-8-dependent joint pain that is associated with ACPA- 
mediated bone loss (52). IL-8 and autoantibodies contribute to neutrophil recruitment into 
the joint, which causes inflammation. Over time, inflammatory cells accumulate in the 
synovium and produce proinflammatory cytokines and pain mediators, leading to chronic 
inflammation and pain (52). 




The outside-in hypothesis posits that inflammation in RA begins in the 
synovium/joint space and then extends to bone. This mechanism starts with autoreactive 
T cells in the joint secreting TNF, IL-17, IFN and RANK-L, activating macrophages 
and fibroblasts. Activated macrophages then secrete pro-inflammatory cytokines (TNF-α, 
IL-1β, and IL-6) that promote the establishment and maintenance of inflammation in the 
synovium (54). Activated T cells also stimulate autoreactive B cells to produce ACPA 
and RF. ACPA actually make up a higher proportion of the total IgG in synovial fluid 
than they do in serum, suggesting that most ACPA are made in the synovium and then 
diffuse into the periphery (23). ACPA, RF, and other autoantibodies can directly activate 
macrophages and complement, further driving inflammation. Activated fibroblasts 
produce RANKL, which promote macrophages to differentiate into osteoclasts (described 
above), and matrix metalloproteases (MMPs) (53,54). These antibodies, osteoclasts, and 
MMPs, along with recruited inflammatory cells, like neutrophils, mediate inflammation- 
dependent cartilage destruction and bone erosion (54). In addition to directly contributing 
to joint destruction, synovial fibroblasts also are involved in spreading of disease. They 
can leave cartilage destruction sites, migrate in the bloodstream, and reinitiate the 







Figure 8: The “Outside-in” Hypothesis of RA Pathophysiology (56) 
 
Regardless of how the disease develops, RA patients necessarily develop 
widespread inflammation. This inflammation and its mediators can lead to a myriad of 
systemic long-term complications. RA is associated with increased rates of 
cardiovascular illness. One mechanism behind this may include the cytokines produced 
from all the inflammation (56). Such cytokines can also lead to insulin resistance in 
muscle and adipose tissue, resulting in an “inflammatory metabolic” syndrome. Other 
extra-articular sites affected in RA can include the brain, liver, muscles, bones, and 
exocrine glands. Dysfunction of these structures is what leads to fatigue, anemia, 
sarcopenia, osteoporosis, and Sjogren's syndrome. The risk of lymphoma is also 
increased in RA patients in a dose-dependent manner, as sustained disease activity 






The goals of RA treatment are disease remission (if possible), prevention of 
disease progression, protecting affected joints from further destruction/pain, and 
increasing joint function. Treatment regimens consist of combinations of 
pharmaceuticals, exercise, patient education, and rest (57,58). When it comes to 
pharmaceuticals, many options have been developed, each with their own targets and 
special considerations. The first lines of defense, nonsteroidal anti-inflammatory drugs 
(NSAIDs) and glucocorticoids, act to quickly relieve pain and swelling and decrease 
inflammation. Both of these types of drugs exert their effect by inhibiting parts of 
cyclooxygenase metabolism and include drugs like acetylsalicylate (Aspirin) and 
ibuprofen (Advil and Motrin). NSAIDs can be taken more often and at higher doses than 
corticosteroids because corticosteroids are more potent and have greater side effects 
(57,58). Glucocorticoids act more broadly to reduce inflammation, but come with 
potentially serious side-effects, like bone loss and type 2 diabetes. To control 
inflammation in the long run, Disease Modifying Anti-Rheumatic Drugs (DMARDs) are 
utilized. It is recommended to start a course of DMARDs as soon as a diagnosis of RA is 
given (57). Methotrexate (MTX) is the initial second-line drug. MTX prevents the 
production of tetrahydrofolic acid (FH4) via competitive inhibition. Without FH4, amino 
acid synthesis in inhibited. This inhibition leads to suppression of inflammation as well as 
prevention of cell division. However, patients on MTX must be closely monitored, since 
it is an immunosuppressive drug, and increases the risk of contracting infection (58). If 




sulfasalazine, and/or leflunomide (57,58). Biologics, also known as biological DMARDs, 
are considered to be a more “direct, defined, and targeted” method of treatment (58). 
However, these are also immunosuppressing drugs with their own challenges. Examples 
of these include TNF inhibitors (i.e.: infliximab, certolizumab, adalimumab, and 
etanercept), interleukin inhibitors (i.e.: Anakinra: IL-1, Tocilizumab: IL-6), and T cell 
inhibitors (i.e.: Abatacept: CD80/86- CD 28) (57,58). Joint surgery can also be performed 






The main purpose of this thesis is to characterize the immune response against 
aberrantly expressed HERV-K proteins in RA patients and explore the hypothesis that the 
expression of such proteins in patient neutrophils may increase citrullination and 
development of ACPA that are characteristic of RA. 
 
 
In doing so, two questions will be addressed: 
 
1. What kind of immune response do RA patients mount against HERV-K? 
 
2. Is there a connection between HERV-K immunity and protein citrullination, 









The University of Washington (UW) Rheumatology Division maintains an active 
centralized Biorepository to support numerous ongoing research projects studying the 
natural history and underlying causes of disease in patients with rheumatic and 
autoimmune disease. This repository draws from the RA patients that each year visit our 
Rheumatology clinic, which is a tertiary referral center for a multi-state region of 
northwestern United States. From this resource, we used sera from de-identified RA 
patients with active disease. Sera is kept at −20 °C until use. We also obtained fresh 
drawn blood from de-identified RA patients (n=10) and healthy donors (n=5) from this 
resource. IRB approval for our study was obtained from the UW ethics board and 




Peripheral blood mononuclear cells (PBMCs) and polymorphonuclear cells 
(PMNs) were isolated from whole blood using Polymorphprep™ (PROGEN), a 
separation medium optimized for human granulocyte isolation. 7 ml of whole blood 
collected in lithium heparin-coated phlebotomy tubes were carefully layered on top of 7 
ml of Polymorphprep in 15ml Falcon conical test tubes. This process was repeated in 
multiple tubes until all of the blood had been utilized. These were then centrifuged at 625 




of blood components can be seen (Figure 9). The top yellow layer of plasma was 
collected and stored at -20°C, the top white band are the PMBCs which were collected 
into a new tube. The lower band are the PMNs, which were also collected into a new 
tube. The pelleted red blood cells (dark layer at the bottom of the tube) were discarded. 
Figure 9:Blood Separated with Polymorphprep 
 
Once isolated, 30 ml of Dulbecco’s phosphate-buffered saline (DPBS) (Gibco) 
was added to each conical (PBMCs and PMNs) and then these were centrifuged at 1500 
rpm for 5 minutes. If the resulting pellet was red, a hemolysis step was performed with 
red blood cell lysis buffer (eBioscience™). After 10 minutes, the hemolysis step was 
stopped by the addition of DPBS. The cells were spun at 1500 rpm for 5 minutes. This 
RBC lysis step was repeated if there were still noticeable red cells in the pellet. The 




added to 90 l Trypan blue (ThermoFisher), and then 10 l of this mixture was loaded 
onto a hemocytometer. 
 
Figure 10: Counting Cells on a Hemocytometer (59) 
 
The number of cells were counted by taking the average of the number of cells in the five 
red squares (Figure 10). This represents how many 10,000 cells there are per ml in the 
solution. The cells were then pelleted and resuspended in the proper amount of DPBS so 




Blood collected in uncoated phlebotomy tubes were allowed to sit upright at room 
temperature (to promote coagulation) for one hour and then spun at 3000 rpm for 12 
minutes at 4ºC. This allowed all the red cells to pellet at the bottom with the remaining 




Proteins and Antibodies Used 
 
Table 1: Proteins and Antibodies Used 
 
 
Antibody/Protein Source ID 
HERV-K Env SU F4 Olympic proteins N/A 
HERV-K Env TM F1 Olympic proteins N/A 
PAD2 Cayman #10785 
PAD4 Cayman Chemicals #10500 
anti-CitEnv Patient derived N/A 
anti-Env Patient derived N/A 
anti-C5b-9 Abcam #GR33126-5 
anti-Citrulline Clone C4 EMD Millipore #3540993 
anti-CD66 Clone G10F eBioscience #2100661 
anti-CD15 Clone HI98 Biolegend #B294906 
anti-CD19 Clone HIB19 Biolegend # B279663 
CD32a/FCRIIA Sino Biological Inc #10374-MM03 






Patient antibody titers against Env and citEnv were quantified using an indirect 
ELISA technique, as previously done in our lab (60). HERV-K Env-SU protein was 
adsorbed onto 96-well polystyrene plates at 50 ng/well in 0.1 M carbonate (pH 9.6) 
buffer overnight, washed in phosphate-buffered saline with Tween, and blocked with 1.5 
µg/ml of poly(Glu, Lys, Tyr) (6:3:1), which lacks arginine residues and therefore cannot 
be citrullinated, for 2 hours. 250 ng of PAD4 and PAD2, each in 100µl Tris-buffered 
saline, pH 7.7, 5 mM CaCl2 and 1 mM DTT was added to specific wells and incubated at 
37°C for 1 hour. Plates were then extensively washed, and RA patient serum was added 
at 0.03% in blocking buffer for overnight incubation at 4°C. The next day, the plates 
were washed extensively and then incubated with 1:2,000 dilution of horse radish 
peroxidase-conjugated anti-human IgG. The reaction was then washed, and developed 
with 3,3’,5,5’-tetramethylbenzidine (TMB, Biolegend), with the color reaction terminated 
with 2N sulfuric acid, and the absorbance measured at 450 nm using a plate reader 
(Synergy, BioTek). A dilution series of a specifically selected and highly reactive RA 
patient was included on every ELISA plate and used to normalize all data points. 
Affinity Purification 
 
Circulating antibodies in patient sera were purified following a previously 
described protocol (60). Briefly, 100 µg of Env-SU protein in 0.1 M carbonate (pH 9.6) 
was immobilized on 3-inch plastic cell culture dishes overnight, followed by several 
washes in phosphate-buffered saline with Tween, and blocking in 2% bovine serum 




5 ml RA patient serum, washed extensively, and the bound antibodies eluted at pH 1 and 
immediately neutralized. A sample of the eluted antibodies was analyzed by sodium 
dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie 
staining. 
To affinity-purify autoantibodies reactive only with citrullinated Env (anti- 
citEnv), the protocol was modified in several ways. First, we used 1.5 µg/ml of poly(Glu, 
Lys, Tyr) (6:3:1) for blocking instead of BSA (because BSA can be citrullinated). 
Second, the plates with immobilized Env-SU were incubated with 500 ng of recombinant 
PAD4 in 500µl Tris-buffered saline, pH 7.7, 5 mM CaCl2 and 1 mM DTT at 37°C for 1 
hour. After extensive washing, the plates were incubated with patient sera, washed, and 
eluted as described above. Lastly, the eluted antibodies were incubated on plates with 
untreated Env-SU to adsorb antibodies reactive with unmodified Env (Figure 11). 






Following SDS-PAGE, the gel was rinsed with water for 5 minutes. 
 
SimplyBlue™ was added to cover the gel and the let to stain for 1 hour at room 
temperature. The gel was then put in water for 1-3 hours to de-stain before imaging. 
Cell Culture and Treatment 
 
Following isolation, PMNs were diluted to 10$cells/ml in Hank’s buffered salt 
solution (HBSS) with 2mM CaCl! and incubated at 37ºC. The following drugs (table 2) 
were added to separate treatment groups, and then cells were pelleted and washed 
(terminating any drug effect) at the time points of 0 and 30 minutes. Control groups 
comprised of cells incubated at 37ºC for 0 and 30 minutes without drug treatment were 
also included. 
Table 2: Drugs Used 
 
 
Drug Manufacturer Concentration Used 
Nigericin Sigma N7143-5MG 1-10 µM 




To prepare cell lysates from isolated cells for western blotting, 5 x 10% cells were 
resuspended in 500µl of Roche lysis buffer (LIFESCIENCE), combined with an equal 





Equal amounts of the protein were loaded (35μl of cell lysate, equivalent to 
35,000 cells) into each well of a 10% SDS-PAGE gel, along with 3 μl of molecular 
weight marker (Precision Plus Protein™ from Biorad). Gels were ran at 180 volts for 45 
minutes. To transfer protein bands to a membrane, polyvinylidene fluoride (PVDF) 
transfer paper was first activated by soaking in methanol for 1 minute and then was 
soaked in transfer buffer before preparing the transfer stack (Figure 11). 200-300 mA 
were applied to the transfer apparatus for 45 minutes. 
 
 
Figure 12: Transfer Stack Used in Wet Protein Transfer (61) 
 
After transferring, membranes were blocked in SuperBlock™ (TBS) Blocking Buffer 
(THERMOFISHER) for 1 hour at room temperature with constant agitation. The 
membrane was then incubated with the desired primary antibody at an appropriate 
dilution in blocking buffer overnight with constant agitation at 4ºC. Following a wash, 
membranes were then incubated with an HRP-conjugated secondary antibody at room 
temperature for 30 minutes. Membranes were washed once more and then developed 
with enhanced chemiluminescent detection system (THERMOFISHER). Images were 




Anti-Modified Citrulline Blot 
 
Following a SDS PAGE and Gel Transfer (described above), the protocol for The 
Anti-Citrulline (Modified) Detection Kit by EMD Millipore (17-347B) was followed 
(62). 5% nonfat dry milk in TBST was substituted with Superblock in TBS 
(THERMOFISHER), and 5 washes in TBST were done for 3 minutes each, with one 
wash containing 1M NaCl. Antibodies were diluted in SuperBlock™ (TBS) Blocking 
Buffer (THERMOFISHER), as well. 
Flow Cytometry 
 
Cells were washed twice in phosphate-buffered saline (PBS) with 1% BSA and 
then stained with a mixture of antibodies against surface antigens: anti-CD66b, anti- 
CD15, and anti-CD19 and against proteins of interest: anti-Env (affinity-purified patient 
antibody), anti-citrullinated Env (affinity-purified patient antibody), and anti-C5b-9 
(which recognizes the membrane attack complex of complement). An antibody to the Fc 
receptor (anti-FCRII) was added to block any nonspecific binding. CD66b is found on 
all granulocytes, CD15 is typically just expressed on neutrophils, and CD19 is found only 
on B Lymphocytes (63,64). Therefore, we categorized any CD66b+CD15+ cells as 
neutrophils. 
Table 3: Fluorophores used 
 
 
Antibody Fluorophore Concentration 





anti-CD15 clone W63D PerCP 1:200 in PBS + 1% BSA 
anti-CD19 clone HIB19 APC-750-A 1:200 in PBS + 1% BSA 
anti-Env Alexafluor 647/APC* 1:50 in PBS + 1% BSA 
anti-CitEnv Alexafluor 647/APC* 1:50 in PBS + 1% BSA 
anti-C5b-9 Alexafluor 488 /FITC* 1:50 in PBS + 1% BSA 
 
 
*Antibodies were conjugated to their fluorophores using the Alexafluor microscale 
protein labeling kit protocol (Invitrogen 2246825, 2208466). 
 
Cells were incubated with these antibodies at 4ºC and shielded from the light for 
30 minutes. Cells were then washed, resuspended in PBS with 1%BSA, and added to 
wells of a 96 well plate with each well containing 1 million cells in 100 µl. Flow 
cytometry was run on a CytoFLEX Flow Cytometer (Beckman Coulter) and data analysis 
was done using FlowJo (Becton, Dickinson and Company). FMO (fluorescence minus 
one) wells were used to determine the cut-off point between background fluorescence and 
positive populations. These wells contained cells stained with all fluorophores used in the 
experiment except one, and thus, were able to serve as a negative control for individual 
fluorophores. Compensation runs were also used to address any potential overlap of 
fluorophore emission. These runs were done using UltraComp eBeads Plus compensation 






Descriptive and inferential statistics were employed using measures of central 
tendency and non-parametric analysis as most data sets were unpaired with non-Gaussian 
distributions. The non-parametric analyses were performed using sign test, Wilcoxon 
signed rank test, Mann-Whitney U-test, and Spearman correlation test as applicable. 
Quantitative data (nominal or ordinal) and qualitative or categorical data were analyzed 
using the appropriate methods. In all analyses, values above the 90th or 95th percentile of 
healthy controls, depending on the data set, was used as the cut-off for positivity, and a p- 
value <0.05 was used as the cut-off for statistical significance. GraphPad Prism and IBM 






During the assembly of HERV-K virions, the Env protein undergoes a proteolytic 
cleavage, resulting in a 50-kDa surface protein (SU) and a 30-kDa transmembrane 
protein (TM). To determine if patient antibodies recognize either of these proteins, we 
performed a western blot with both of these proteins, using patient sera (diluted 1:10 in 
Superblock) as the primary antibody, and a corresponding anti-human HRP-conjugated 
secondary antibody. Patient sera exhibited a strong reactivity with the SU protein, but 
little to no reactivity with the TM protein (ours lacks the intracellular region and is only 
20 kDa). Healthy volunteer sera were also used and showed no-to-minor reactivity with 





















Figure 13: Western Blots of HERV-K SU (top) and HERV-K TM (Bottom) with 


























This SU protein was then used to optimize anti-Env ELISAs. Patient sera 
determined to have high anti-Env SU titers from these ELISAs (Figure 15) were used to 
affinity purify an antibody to HERV-K Env. This antibody was fluorescently conjugated 
and used for flow cytometry analysis. Flow cytometry showed that RA patients do have 
an increased presence of Env protein compared to controls, however, it is a small number 

























Figure 14: Flow Cytometry with Patient (A&B) and Control (C&D) PMNs 
A&C: anti-HERV-K Env, CD66, and CD15 labels. 
B&D: CD66, and CD15 labels (FMO/negative control run). 
Left column: total Env labeled cells; Middle column: double positive CD66/Env cells; 





stain that showed the correct weights for the heavy and light chains of the antibody 
(Figure 16). 
Figure 16: Coomassie Stain of Affinity-purified Patient Autoantibodies Against 
Citrullinated Env-SU 
We used the affinity-purified anti-citEnv autoantibodies in western blots with 
lysates of PMN and PBMC from RA patients. These experiments repeatedly gave a 
single band at 50 kDa, which is the predicted relative molecular weight (Mr) of the SU 









Figure 17:Western Blot of RA Patient PMNs with Affinity-purified Anti-citEnv 
 
We also conjugated these affinity-purified antibodies to Alexa Fluor-647 and used 






























stained a subpopulation of CD15+/CD66b+ neutrophils. In contrast, only a very small 
































Figure 18: Flow Cytometry with Patient (A&B) and Control (C&D) PMNs 
A&C: anti-HERV-K CitEnv, CD66, and CD15 labels. 
B&D: CD66, and CD15 labels (FMO/negative control run). 
Left column: total CitEnv labeled cells; Middle column: double positive CD66/CitEnv 




Statistical analyses were done comparing the data from anti-Env (Figure 14) flow 
cytometry experiments and anti-citEnv (Figure 18) flow cytometry experiments. When 
comparing how many cells were positive for the protein of interest (Env or CitEnv), 
patient PMNs tended to have more citEnv positive cells than Env positive cells. Patient 
PBMCs and healthy control PMNs and PBMCs don’t show much of a difference between 
the two. 
Figure 19: Statistical Analyses of Flow Cytometry Experiments 
 
AMC blots were used to measure the general amount of citrullination present in 
cells. Isolated PMNs were treated with ionomycin and nigericin (both of which act to 
induce citrullination) for either 0 or 30 minutes. The cells from each treatment group 
were then prepared as cell lysates to be used in the AMC blot protocol. AMC blots label 
citrulline residues and our blots demonstrate that PMNs experience an increase in 








Figure 21: Flow Cytometry with Patient (A&B) and Control (C&D) PMNs 
A&C: C5b-9, CD66, and CD15 labels. 
B&D: CD66, and CD15 labels (FMO/negative control run). 
Left column: total C5b-9 labeled cells; Middle column: double positive CD66/ C5b-9 
































Patient Immune Response to HERV-K 
 
Our experiments showed that RA patients produce antibodies against the HERV- 
K Env protein, an idea echoed in the established literature. This suggests that loci 
encoding HERV-K proteins are, or recently were, transcriptionally active and led to the 
translation of immunogenic viral proteins in seropositive patients. The fact that the SU 
portion of this protein is recognized more, and with increased intensity compared to the 
TM portion is unsurprising due to the relative locations of the two in vivo. However, the 
fact that some patients do have antibodies against the TM portion provides even stronger 
support for the idea that HERV-K is, in fact, expressed in some cells. 
HERV-K and Citrullination 
 
Our experiments showed that RA patients not only had antibodies that recognize 
citrullinated Env, but that many more patients had autoantibodies against citrullinated 
Env than against unmodified Env. This poses the question: why would citrullinating 
enzymes, such as PAD2 and PAD4, act on viral proteins? We speculate that this 
citrullination is a defense mechanism against viruses. It has been shown that when 
infectious, HERV-K used heparan sulfate-containing proteins as its cellular receptors, 
followed by receptor-mediated endocytosis and low pH-triggered fusion by the Env 
protein (65). It is likely that basic charges on Env-SU was involved in this process (65). 
Therefore, the citrullination of arginine residues would decrease the basic charge of the 




Even if the exogenous HERV-K no longer exists, this defense mechanism could still be 
functioning. This could explain why we detect citrullinated Env on RA neutrophils. This 
would not be the first example of this mechanism: an Epstein-Barr Virus protein has been 
shown to be citrullinated and recognized by ACPA (17). 
Our experiments also showed the presence of the membrane attack complex of 
complement on RA PMNs. This suggests that for some reason, the complement cascade 
is targeting neutrophils. There are several ways that complement can be activated, one 
being antibody binding. Therefore, since increased citEnv is expressed on RA PMNs (as 
exhibited in our flow cytometry data), ACPAs recognizing this protein could bind and 
activate complement, leading to neutrophil lysis and further hypercitrullination as PADs 
are released into the extracellular space. 
Conclusions 
 
While our data are promising, there is the need for further experimentation. First 
and foremost, more experiments are required to bolster the significance, and in turn, 
relevance of the results presented in this thesis. Additionally, more experimentation is 
required to confirm assumptions we have made. For example, to explore if citrullination 
serves as a protective mechanism against viral infection, a competition assay can be 
performed to see if patient antibodies block heparin-agarose binding (an easily measured 
property of the Env protein). Additionally, to further explore the expression of Env on 
PMNs, RA patient and control PMNs could be stained with fluorescently conjugated 
Anti-Env antibodies and imaged with immunofluorescent microscopy. Due to the cell 
surface location of the Env protein, the cells that express the protein could be easily 
44 
identified. Lastly, further research into how HERV-K transcription leads to such a 
localized reaction, as it does in RA, is needed. Is HERV-K expression somehow 
preferentially restored in synoviocytes? Or is expression systemic, but it’s effects remain 
localized to the joint, potentially through migration of neutrophils, the primary 
inflammatory mediators recruited to the joints? Regardless of the mechanism, it requires 
a complex multifactorial interplay between numerous genetic and environmental factors. 
Ultimately, establishing a significant connection between HERV-K and pathological 
citrullination will allow us to achieve a greater understanding of RA pathogenesis and 
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